These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 1397048

  • 1. Dopamine receptor occupancy in vivo: behavioral correlates using NNC-112, NNC-687 and NNC-756, new selective dopamine D1 receptor antagonists.
    Nielsen EB, Andersen PH.
    Eur J Pharmacol; 1992 Aug 14; 219(1):35-44. PubMed ID: 1397048
    [Abstract] [Full Text] [Related]

  • 2. NNC-112, NNC-687 and NNC-756, new selective and highly potent dopamine D1 receptor antagonists.
    Andersen PH, Grønvald FC, Hohlweg R, Hansen LB, Guddal E, Braestrup C, Nielsen EB.
    Eur J Pharmacol; 1992 Aug 14; 219(1):45-52. PubMed ID: 1397049
    [Abstract] [Full Text] [Related]

  • 3. Long-term treatment with low doses of the D1 antagonist NNC 756 and the D2 antagonist raclopride in monkeys previously exposed to dopamine antagonists.
    Lublin H, Gerlach J, Mørkeberg F.
    Psychopharmacology (Berl); 1994 Apr 14; 114(3):495-504. PubMed ID: 7855208
    [Abstract] [Full Text] [Related]

  • 4. Chronic dopamine D1, dopamine D2 and combined dopamine D1 and D2 antagonist treatment in Cebus apella monkeys: antiamphetamine effects and extrapyramidal side effects.
    Peacock L, Hansen L, Mørkeberg F, Gerlach J.
    Neuropsychopharmacology; 1999 Jan 14; 20(1):35-43. PubMed ID: 9885783
    [Abstract] [Full Text] [Related]

  • 5. Chronic treatment with the D1 receptor antagonist, SCH 23390, and the D2 receptor antagonist, raclopride, in cebus monkeys withdrawn from previous haloperidol treatment. Extrapyramidal syndromes and dopaminergic supersensitivity.
    Lublin H, Gerlach J, Peacock L.
    Psychopharmacology (Berl); 1993 Jan 14; 112(2-3):389-97. PubMed ID: 7871047
    [Abstract] [Full Text] [Related]

  • 6. Interactions between D1 and D2 dopamine receptor family agonists and antagonists: the effects of chronic exposure on behavior and receptor binding in rats and their clinical implications.
    Braun AR, Laruelle M, Mouradian MM.
    J Neural Transm (Vienna); 1997 Jan 14; 104(4-5):341-62. PubMed ID: 9295170
    [Abstract] [Full Text] [Related]

  • 7. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation.
    Hess EJ, Albers LJ, Le H, Creese I.
    J Pharmacol Exp Ther; 1986 Sep 14; 238(3):846-54. PubMed ID: 3018223
    [Abstract] [Full Text] [Related]

  • 8. SCH-23390: a selective D1 dopamine antagonist with potent D2 behavioral actions.
    Mailman RB, Schulz DW, Lewis MH, Staples L, Rollema H, Dehaven DL.
    Eur J Pharmacol; 1984 May 18; 101(1-2):159-60. PubMed ID: 6235121
    [No Abstract] [Full Text] [Related]

  • 9. PET studies of binding competition between endogenous dopamine and the D1 radiotracer [11C]NNC 756.
    Abi-Dargham A, Simpson N, Kegeles L, Parsey R, Hwang DR, Anjilvel S, Zea-Ponce Y, Lombardo I, Van Heertum R, Mann JJ, Foged C, Halldin C, Laruelle M.
    Synapse; 1999 May 18; 32(2):93-109. PubMed ID: 10231129
    [Abstract] [Full Text] [Related]

  • 10. Dopamine receptor antagonist properties of S 14506, 8-OH-DPAT, raclopride and clozapine in rodents.
    Protais P, Chagraoui A, Arbaoui J, Mocaër E.
    Eur J Pharmacol; 1994 Dec 12; 271(1):167-77. PubMed ID: 7698199
    [Abstract] [Full Text] [Related]

  • 11. D1 and D2 dopamine receptor-mediated mechanisms and behavioral supersensitivity.
    Marin C, Parashos SA, Kapitzoglou-Logothetis V, Peppe A, Chase TN.
    Pharmacol Biochem Behav; 1993 May 12; 45(1):195-200. PubMed ID: 8516358
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions.
    Ogren SO, Hall H, Köhler C, Magnusson O, Sjöstrand SE.
    Psychopharmacology (Berl); 1986 May 12; 90(3):287-94. PubMed ID: 2947255
    [Abstract] [Full Text] [Related]

  • 17. Effects of D2 or combined D1/D2 receptor antagonism on the methamphetamine-induced one-trial and multi-trial behavioral sensitization of preweanling rats.
    Mohd-Yusof A, Veliz A, Rudberg KN, Stone MJ, Gonzalez AE, McDougall SA.
    Psychopharmacology (Berl); 2016 Mar 12; 233(5):893-903. PubMed ID: 26650612
    [Abstract] [Full Text] [Related]

  • 18. Cocaine-induced behaviour: dopamine D1 receptor antagonism by SCH 23390 prevents expression of conditioned sensitisation following repeated administration of cocaine.
    McCreary AC, Marsden CA.
    Neuropharmacology; 1993 Apr 12; 32(4):387-91. PubMed ID: 8497339
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Dopamine D1 and D2 receptor antagonism during development alters later behavior in zebrafish.
    Oliveri AN, Levin ED.
    Behav Brain Res; 2019 Jan 01; 356():250-256. PubMed ID: 30172631
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.